Precigen Fast Tracked for Acute Myeloid Leukemia

 – Acute myeloid leukemia (AML) is among the most common types of leukemia in adults –

– PRGN-3006 UltraCAR-T previously received orphan drug designation (ODD) in patients with AML by the US Food and Drug Administration (FDA) –

– PRGN-3006 UltraCAR-T has demonstrated a favorable safety profile to date with no dose-limiting toxicities or neurotoxicity, and has demonstrated dose-dependent in vivo expansion and durable persistence –

https://finance.yahoo.com/news/precigen-receives-fast-track-designation-120500568.html